Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235961 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL30341002 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL5577937 | 0.87 | KDM4E (0.74) | ALDH1A1KDM4EGAALMNAMEN1 | |
| SCHEMBL2096006 | 0.87 | KDM4E (0.74) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL3155705 | 0.87 | ALDH1A1 (0.74) | ALDH1A1KDM4EGAALMNACNR2 | |
| SCHEMBL2093612 | 0.85 | KDM4E (0.72) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL1761029 | 0.85 | ALDH1A1 (0.72) | ALDH1A1KDM4EGAALMNACNR2 | |
| SCHEMBL6928385 | 0.85 | KDM4E (0.72) | ALDH1A1KDM4EGAALMNAMEN1 | |
| SCHEMBL4240373 | 0.85 | ALDH1A1 (0.72) | ALDH1A1KDM4EGAALMNACNR2 | |
| SCHEMBL29671377 | 0.85 | KDM4E (0.72) | ALDH1A1KDM4EGAALMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123165-A1 | KINASE INHIBITORS | INSILICO MEDICINE LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
| EP-2729141-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR AGONISTS | Rottapharm Biotech Srl (IT) | 2015-12-09 | — | — | EP | disclosed |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | ALDH1A1 77/4885KDM4E 866/4885GAA 644/4885 |
| US-20200123165-A1 | KINASE INHIBITORS | DDR1, DDR2, DDRGK1 | ALDH1A1 4080/4885KDM4E 811/4885GAA 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.